{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001743881","name":"BridgeBio Pharma, Inc.","summary":"BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. It operates a decentralized hub-and-spoke model and has received FDA approval for three products: Attruby (acoramidis) for ATTR-CM, Nulibry (fosdenopterin) for MoCD Type A, and Truseltiq (infigratinib) for cholangiocarcinoma (withdrawn). Attruby generated $362.4 million in U.S. net product revenues in 2025. The company also has multiple Phase 3 programs in achondroplasia, LGMD2I/R9, and ADH1.","people":[],"products":[{"name":"Attruby (acoramidis)","type":"service","description":"FDA-approved oral small molecule near-complete TTR stabilizer for ATTR-CM in adults, reducing cardiovascular death and hospitalization."},{"name":"Beyonttra (acoramidis)","type":"service","description":"Brand name for acoramidis marketed outside the U.S., approved in Europe, UK, Switzerland, and Japan for ATTR-CM."},{"name":"Nulibry (fosdenopterin)","type":"service","description":"FDA-approved treatment for Molybdenum Cofactor Deficiency Type A."},{"name":"Truseltiq (infigratinib)","type":"service","description":"Previously FDA-approved treatment for cholangiocarcinoma; approval subsequently withdrawn."},{"name":"Infigratinib (ACH)","type":"service","description":"Oral therapy in Phase 3 for achondroplasia; PROPEL 3 study met all primary and secondary endpoints in February 2026."},{"name":"BBP-418","type":"service","description":"Phase 3 therapy for limb-girdle muscular dystrophy type 2I/R9; FORTIFY study met primary and key secondary endpoints in October 2025."},{"name":"Encaleret","type":"service","description":"Phase 3 therapy for autosomal dominant hypocalcemia type 1 and chronic hypoparathyroidism; CALIBRATE trial showed positive topline results in October 2025."}],"partnerships":[{"partner_name":"Bayer","partnership_type":"licensing","description":"Exclusive license for commercialization of Beyonttra (acoramidis) in EU member states, UK, Switzerland, and Turkey; agreement signed March 2024.","start_date":null},{"partner_name":"Alexion, AstraZeneca Rare Disease","partnership_type":"licensing","description":"Exclusive license for commercialization of Beyonttra (acoramidis) in Japan; agreement signed September 2019.","start_date":null}],"affiliations":[],"origin":{"leaf":"04adba50342e3742d5e26cc2b98b8938a9f83229f44f19072a4c31d3a057ea83","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"398dac35650ce783ec96aeebaf26efed21405d10479f2dc8be5bc631778d61e7","parent":"19ee51b1811177826bd116df51354be2e17b814630255edd9f8726dd9eb5a48a","source":"0001743881-26-000009","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}